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Tumor  necrosis  factor  (TNF) 1 is  a  monocyte/macrophage-derived  protein 
whose major role is presumed to be mediation of cytotoxicity for tumor cells (1). 
TNF is structurally and functionally related to lymphocyte-derived lymphotoxin 
(2).  TNF and lymphotoxin are cytotoxic or cytostatic for some types of tumor 
cells; in contrast, nontransformed cell lines are generally resistant to the cytotoxic 
and cytostatic actions of these two proteins (3, 4). 
In a recent study we used 12~I-labeled recombinant human TNF to analyze its 
interaction  with  cell  surface  receptors  (5).  We  found  that  murine  L929  cells 
(susceptible  to  the  cytotoxic  action  of TNF)  as  well  as  human  diploid  FS-4 
fibroblasts (completely resistant to TNF cytotoxicity) have a  similar number of 
specific high-affinity binding  sites for TNF.  In  both cell lines binding of TNF 
was followed by its receptor-mediated endocytosis, and intracellular degradation 
by a process inhibited in the presence of the lysosomotropic agent, chloroquine. 
In a related study (6), we analyzed TNF receptors in five human tumor cell lines. 
The number of TNF binding sites per cell ranged  from ~5,000-20,000,  with 
the  apparent  Kd ranging  from  1.6-2.4  X  10 -1°  M.  No  correlation  was found 
between  the  number  of TNF  receptors  or  their  affinity  for  TNF  and  the 
susceptibility of cells to  the  cytotoxic action  of TNF.  These  results  suggested 
that,  in  cells resistant  to TNF  cytotoxicity, TNF receptors may mediate  some 
other biological activity. Beutler et al.  (7) recently reported  that  TNF may be 
closely related or identical to a  macrophage-secreted protein termed cachectin, 
defined as a hormone inhibiting lipoprotein lipase activity. Earlier, Beutler et al. 
(8) had shown the presence of specific receptors for cachectin in several normal 
routine tissues. 
In our study,  we investigated the ability of TNF to stimulate  the growth of 
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diploid human  FS-4 fibroblasts. Stimulation of cell growth was demonstrable at 
TNF concentrations of 10-12-10213 M, i.e., equal to or lower than TNF concen- 
trations shown to produce cytotoxicity in highly sensitive transformed cell lines. 
We also show that,  in promoting cell growth,  TNF  can act synergistically with 
insulin.  These  data  suggest  that  stimulation  of cell  growth  is  a  physiological 
function  associated with TNF.  Along with the  findings of Beutler et al.  (7,  8), 
our  data  show  that  inhibition  of tumor  cell  growth  is  not  the  only biological 
activity mediated by TNF. 
Materials and  Methods 
Materials.  Recombinant E. coli human TNF was produced and purified to 4.8 ×  107 
U/mg sp act at the Suntory  Institute for Biomedical Research. The material appeared 
homogeneous (Mr  17,000) when analyzed by SDS-PAGE) (5).  A  single lot of TNF was 
used in all experiments. Recombinant E. coli-derived human  IFN-~, (sp act, 2.1  ×  107 
U/mg based on international National Institutes of Health IFN-~ reference standard Gg- 
23-901-530)  was provided by Biogen, Cambridge, MA.  Natural human IFN-13 partially 
purified to >_106 U/rag sp act (based on international human IFN-/3 reference standard 
G-023-902-527),  was  prepared  by  Bioferon  GmbH,  Laupheim,  Federal  Republic  of 
Germany. Epidermal growth factor (EGF) was purchased from Collaborative Research, 
Lexington, MA.  Purified porcine insulin was kindly provided by Dr. Bernard Aitshuler 
of New York University Medical Center. 
Assay of TNF Cytotoxicity.  Determination of TNF activity was based on an assay for 
cytotoxicity in a TNF-susceptible subline of L929 cells at 40°C as described (5). Potency 
is expressed in units per milliliter based on the reciprocal of the highest dilution producing 
50%  cell  lysis.  Each  assay was standardized  by the  inclusion  of a  laboratory reference 
preparation of TNF. 
mAb Against TNF.  Two murine mAbs, produced by immunization with recombinant 
E. coli-derived human TNF, were employed (M.  Hirai and H. Nakazato, manuscript in 
preparation),  mAb TI  was shown to neutralize the cytotoxic activity of TNF (1  #g of 
purified T1  IgG neutralized -40 U of TNF). mAb T2 showed specific binding to TNF 
but lacked neutralizing activity for T N F in the cytotoxicity assay. Both mAbs (IgG  1) were 
used in purified form and stored in preservative-free PBS.  An unrelated  murine mAb 
3D 11 of the same isotype was used as control (kindly provided by Drs. A. Ferreira and V. 
Nussenzweig of New York University Medical Center). 
Assay of Cell  Growth-Stimulatory  Activity of TNF.  All  experiments used  the  human 
diploid FS-4  fibroblast line, isolated at the  New York University Medical  Center from 
foreskin tissue (9).  FS-4 cells were cultured  in  Eagle's MEM supplemented with  6  mM 
Hepes, 3  mM Tricine (N-tris(hydroxymethyl)methylglycine), 50 #g/ml gentamycin, and 
5% heat-inactivated (56°C,  30 min) FCS.  Experiments were done with cells at passage 
level 12-14 (with each passage corresponding to approximately two cell generations). To 
evaluate the effect of TNF on FS-4 cell growth, cells were seeded in 96-well plates (8,000 
cells/well) and cultured in a CO2 incubator at 37°C. TNF and/or other materials to be 
tested were added 18 h after the seeding of cultures. Four to six replicate wells were used 
for each experimental condition. At intervals, plates were removed from the incubator, 
medium was removed by rapid decanting, and the cells were stained with a solution of 
0.05% naphthol blue black (Aldrich Chemical Co., Milwaukee, WI) in 9% acetic acid with 
0.1  M sodium acetate (50 #l/well).  After 30 min the stain was poured off and the cells 
were fixed for  15  min with  10%  formalin in the same acetic acid-acetate buffer. The 
plates were then washed with distilled H20, and the dye was eluted by adding 50 mM 
NaOH  (150  #l/well).  Absorbance  of each  well  was  read  at  630  nm  on  a  Dynatech 
Minireader II. Results are expressed as means (+_SD) of four to six individual values. It 
was determined in preliminary experiments that OD6s0 dye uptake values correlate with 
the  cell  numbers  determined  by detachment  with  a  trypsin  solution  and  microscopic 
counting in a  hemocytometer. The staining method used for the determination of cell 
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[3H]TdR Incorporation.  FS-4  cells were seeded in 96-well plates (8,000 cells/well) in 
MEM with 5% FCS. After 18 h incubation, TNF was added at different concentrations 
to groups of six wells, and the cultures were incubated for 76 h. [SH]TdR (78 Ci/mmol; 
New England Nuclear, Boston, MA) was added to wells (0.5 #Ci/well) during the last 18 
or 6 h of incubation.  The culture medium was then removed, wells were washed twice 
with saline, and the cells were detached by the addition of a solution of 0.25% trypsin 
with 0.02% EDTA and vigorous shaking. The cell suspension was then harvested  with 
the aid of a Skatron cell harvester (Flow Laboratories, McLean, VA) and lysed  by washing 
with distilled H20. Radioactivity bound to the filter was measured in a liquid scintillation 
counter. [SH]TdR incorporation  in human fibroblasts determined by this procedure was 
shown by others to be a correlate  of cell growth (11). 
Results 
Stimulation  of FS-4 Cell Growth by Different Concentrations of TNF.  In initial 
experiments, the ability of TNF to stimulate the growth of FS-4 fibroblasts was 
studied  in  60-ram  dish  cultures  by  a  comparison  of cell  counts  in  cultures 
trypsinized at different times after the addition of various TNF concentrations, 
and  in  control  cultures.  An  increase  in  the  number of ceils  per  culture was 
observed after the addition of a  wide range of TNF doses (data not shown). 
Under the microscope, cells cultured in the presence of TNF appeared manifestly 
denser and more spindle-shaped. Further evaluations of the growth-stimulatory 
activity of TNF were performed in 96-well plates, with cell density determined 
by the staining of cell monolayers with naphthol blue black solution, dye elution, 
and determination of absorbance at 630  nm as described in the Materials and 
Methods. 
Addition of TNF to the culture medium resulted in a demonstrable growth- 
stimulatory activity by 4 d after seeding (Fig.  1). Some stimulation of cell growth 
was seen at a TNF dose of 10 pg/ml (3  ×  10 -13 M). The concentration needed 
to produce an optimal stimulation of cell growth (10 ng/ml or 3 ×  10  -1° M) was 
equal to the apparent Kd of TNF binding to its receptor, determined in FS-4 (5) 
and other human cells (6),  suggesting that growth stimulation results from an 
interaction of TNF with its receptor. 
To confirm that growth stimulation was indeed due to TNF, we examined the 
effect of several mAb on the ability of recombinant TNF to stimulate cell growth 
(Table  I).  Stimulation of cell growth was inhibited in the presence of T1,  an 
mAb with potent neutralizing activity for the cytotoxic action of TNF. Growth- 
stimulatory action was  not inhibited by T2,  an mAb specific for TNF, which 
lacks neutralizing activity for the cytotoxic action of TNF. An unrelated murine 
mAb, 3D11, also did not inhibit TNF's growth-stimulatory action. 
Stimulation  of [3H]TdR Incorporation by TNF.  Stimulatory activity of TNF 
was also demonstrable by an assay of [3H]TdR incorporation in FS-4 cells (Fig. 
2).  In this assay, the degree of stimulation was even more marked than in the 
assay measuring the increase in cell density, but the dose-response relationship 
was similar, as in the experiment shown in Fig. 1, i.e., maximal enhancement of 
[~H]TdR incorporation was attained with TNF doses of 10 ng/ml or higher. 
Stimulation of Cell Growth in the Presence of Different FCS Concentrations.  To 
analyze the mechanism of the growth-stimulatory activity of TNF, we examined 
the  action  of TNF  on  cell  growth  in  cultures maintained in  the presence  of 
different concentrations of FCS. At the same time, we also examined the effect VILCEK  ET  AL.  635 
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FIGURE  1.  Stimulation of cell  growth by different concentrations of TNF.  FS-4 cells were 
seeded in 96-well  plates in  MEM  with  5%  FCS.  After  18  h  incubation, TNF  was added at 
various concentrations as indicated. The cultures were then incubated in a  CO2 incubator at 
37 °C. Plates were removed at different intervals for staining and determination of cell density 
as described in the Materials and Methods. 
TABLE  I 
Inhibition of Growth-stimulatory Activity of TNF in FS-4 Cells by mAb T1 
Cell density (OD~so x  10 2)  Cell density (OD6so X  10 2) 
Treatment  on day 4  SI* (day 4)  on day 6  SI* (day 6) 
with mAb* 
Without TNF  With TNF  Without TNF  With TNF 
None  37 _+ 1.0  57 _  5.0  1.54  44 _  1.5  77 +_ 2.8  1.75 
T1  38_+5.2  33_+6.7  0.87  45_+1.9  50_+2.5  1.11 
T2  36 +  2.1  66 +  2.0  1.83  44 _+ 2.2  77 -4- 1.8  1.75 
3D11  35 -+ 1.9  63 -+ 3.2  1.80  44 -+ 2.6  75 _+ 1.5  1.70 
FS-4 cells were seeded in 96-well plates. After 18 h, TNF was added as indicated. Control cultures 
remained  untreated  or  were  incubated  with  mAb  in  the  absence  of  TNF.  Cell  density  was 
determined 4  and 6 d  after seeding, as described in the Materials and Methods. 
* TNF  (1  ng/ml) was incubated for I  h  at 37°C with mAb (10 #g/ml) as indicated. 
* Stimulation index (With TNF/Without  TNF). 
of IFN-3, on the growth-stimulatory action of TNF (Fig. 3). Growth stimulation 
was seen with TNF at all FCS concentrations used. In cultures maintained with 
lower FCS concentrations,  the stimulatory action of TNF tended to level off by 
the  seventh  day of culture.  In  contrast,  in  cultures  maintained  in  10  or  20% 
FCS, the stimulatory action TNF was more sustained, with cell density increasing 
throughout the observation period. These results suggested that optimal stimu- 
lation of cell growth by TNF requires the contribution of other growth factor(s) 
present  in  FCS.  IFN-7  at  the  dose  of  200  U/ml  completely  inhibited  the 
stimulation  of cell growth by TNF at all  FCS concentrations.  Although  IFN-3, 636  FIBROBLAST  GROWTH  STIMULATED  BY  TUMOR  NECROSIS  FACTOR 
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FIGURE 2.  Stimulation of [SH]thymidine uptake by different concentrations of TNF. Seeding 
of cultures and incubation  with TNF was as in the experiment shown  in Fig.  1. Cells were 
s  then incubated in the presence or absence of TNF until 5 d after seeding. [ H]TdR was added 
for the last 6 or 18 h of incubation and its incorporation  was determined as described in the 
Materials and Methods. 
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FIGURE 3.  Stimulation of cell growth by TNF and its inhibition by IFN-~,: dependence on 
FCS  concentration. Cells  were seeded  in  96-well  plates  in MEM  with  FCS  concentrations 
ranging from 0.625 to 20% as indicated.  After the attachment  of cells TNF (1,000 ng/ml) 
and/or IFN-? (200 U/ml) were added as indicated. Cell density was determined after different 
times of incubation as described in the Materials and Methods. 
did  not  inhibit  cell  growth  in  the  absence  of  TNF  at  the  two  lowest  FCS 
concentrations, a  decrease in cell number below that of the control cultures was 
observed  in  the presence  of IFN-'y  in cultures maintained with FCS  concentra- 
tions of ->2.5%. 
Stimulation of Cell Growth by TNF in Confluent Cultures.  The  growth-stimula- 
tory effect  of the addition of TNF  to confluent  FS-4  cells was examined  either 
in serum-free medium or in medium with fresh 5% FCS (Fig. 4). Some stimulation 
of cell growth occurred after the addition of TNF  to confluent cultures in serum- 
free medium. However,  the growth-stimulatory effect of TNF  in confluent cells V1L(~EK ET  AL.  637 
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FIGURE 4.  Stimulation of cell growth by TNF addition to confluent cultures: dependence 
on the presence of FCS. Cells were seeded in MEM  with  5%  FCS. The cultures reached 
confluence 5-6 d after seeding. After 7 d  of incubation (day 0 in the graph), the original 
medium was removed, the cultures were washed twice with serum-free MEM and re-fed with 
fresh MEM  either containing 5%  FCS or free of serum.  In addition, half of the cultures 
received TNF (10 ng/ml) as indicated. Cell density was determined after different periods of 
incubation, as in the previous experiments. 
FIGURE 5.  Stimulation of cell growth in confluent cultures by TNF: comparison with EGF 
and insulin. Cells were grown to confluence in MEM with 5% FCS as in the experiment shown 
in Fig. 4. After 7 d, the original medium was discarded, and fresh serum-free MEM was added 
containing TNF (25 ng/ml), EGF (25 ng/ml), and insulin (60 #g]ml), as indicated. Cell density 
was determined 6 d after growth factor addition, as in the earlier experiments. C, control; T, 
TNF; E, EGF; 1, insulin. 
was  much  more  marked  in  the  presence  of 5%  FCS.  These  results  show  that 
TNF  can  stimulate  cell  growth  in  contact-inhibited  FS-4  cells,  and  that  this 
stimulatory action is enhanced  by some factor(s) present in FCS. 
Comparison  of TNF,  EGF,  and  Insulin  in Ability  to Stimulate  Cell  Growth  in 
Confluent Cultures in Serum-free Medium.  The  ability of TNF,  EGF, and insulin, 
added  singly or  in  various  combinations,  to  stimulate  the  growth  of confluent 
FS-4  cells in  serum-free  medium  was  examined  (Fig.  5).  Both  TNF  and  EGF 
were employed  at concentrations found to be optimal for growth stimulation in 
FS-4 cells (data for  EGF not shown).  While insulin alone produced  little stimu- 
lation, both TNF  and  EGF showed marked  synergism with insulin. In contrast, 638  FIBROBLAST  GROWTH  STIMULATED  BY  TUMOR  NECROSIS  FACTOR 
the actions of TNF and EGF were less than additive, suggesting that TNF and 
EGF may activate similar or identical pathways. These results suggest that insulin 
or insulin-like growth factor(s) (12) probably are the major component(s) in FCS 
responsible for the observed potentiation  of the growth-stimulating  activity of 
TNF by FCS. 
Discussion 
Monocyte-derived  TNF  (1),  and  the  structurally  and  functionally  related 
lymphocyte-produced  lymphotoxin  (13,  14)  are  generally  defined  as  proteins 
with  cytotoxic or  cytostatic activities against  some types of transformed  cells. 
The primary function of TNF and  lymphotoxin is believed to be mediation of 
host defenses against malignancies.  It has recently been suggested (15) that TNF 
may also have a role in the defense against parasitic infections because partially 
purified  TNF  from  mouse  or  rabbit  sera  showed  a  direct  lethal  effect  on 
Plasmodium yoelii malarial parasites. Beutler et al. (7, 8) found that TNF is closely 
related,  or possibly identical  to another  monocyte-derived protein,  cachectin, 
whose function is to inhibit lipoprotein lipase activity. Accumulation of cachectin 
in animals during parasitic and bacterial infections is thought to be responsible 
for some toxic manifestations and cachexia (16). 
While investigating cytotoxic activities of natural  human  lymphotoxin against 
tumor cells,  Lee et al.  (17) observed that,  in some normal  or transformed  cell 
lines, lymphotoxin not only did not inhibit,  but actually stimulated cell growth. 
In this study, we examined the cell growth-stimulatory activity of highly purified 
recombinant human TNF in the FS-4 line of human diploid foreskin fibroblasts. 
Stimulation  of cell growth was observed at TNF concentrations  between  10  -12 
and 10 -13 M, i.e., at concentrations equal to or actually lower than those required 
for the cytotoxic activity of TNF in tumor cell lines rendered highly sensitive to 
the lytic action of TNF by mitomycin C or incubation at 40°C (our unpublished 
data). Thus, the specific activity of TNF as a growth-stimulatory agent is at least 
as high as that of EGF, an Mr 6,000 polypeptide growth factor whose mechanism 
of action  has  been  extensively studied  (18).  However,  when  used  at  optimal 
concentrations,  EGF did exert a  stronger stimulation  of FS-4 cell growth than 
TNF (Fig. 5). 
Several distinct  serum-derived  growth  factors are needed for cell cycle pro- 
gression in animal cells. A combination ofplatelet-derived growth factor (PDGF), 
EGF, and insulin (used at hyperphysiological concentrations to mimic the action 
of somatomedin  C)  was  shown  to  promote  traversion  of quiescent  3T3  cells 
through Gl to DNA synthesis (19, 20). Although we noted a certain similarity in 
the actions of TNF and EGF, more work is needed to determine at which stage 
in the cell cycle TNF is exerting its growth stimulating activity. It seems unlikely 
that  TNF  interacts  with  the  EGF  receptor,  as  is  the  case  with  transforming 
growth  factor (TGF)-a (21).  Unlike  TGF-a,  TNF does not share  an  apparent 
structural  homology with EGF. Moreover, we found that EGF did not compete 
with the binding of 125I-TNF is FS-4 cells (data not shown). However, it is possible 
that  binding  of TNF  to  its  cell  surface  receptors  triggers  a  similar  series  of 
biochemical changes, as seen with other known growth factors, including EGF, 
PDGF, or TGF-a.  Such changes  might  involve an activation  of protein  kinase VILCEK  ET  AL.  639 
(22, 23), and induction of cellular genes involved in the regulation of the cell 
cycle, including c-myc (24) and c-fos (25). 
The finding that mAb T 1 neutralized both the cytotoxic and growth-enhanc- 
ing activities of TNF,  while another mAb specific for TNF  (T2)  neutralized 
neither (Table  I)  suggests that  the same epitope  of TNF  is  needed for both 
activities. Our earlier studies (5, 6) showed that different transformed human 
cell lines, as well as FS-4 cells, have a single class of high-affinity TNF receptors, 
suggesting that the same type of TNF receptor mediates cytotoxic or cytostatic 
activity in some cells and growth stimulation in others. 
Although it is intriguing that one protein can be cytotoxic or cytostatic for 
some cell lines and growth stimulatory for others, such dichotomy is not without 
precedent. For instance, cholera toxin was reported to both inhibit and stimulate 
DNA synthesis and cell division, depending on the cell type examined (26, 27). 
Iwata et at. (28) recently identified a  tumor cell growth-inhibiting factor (TIF- 
1) from conditioned media of a human rhabdomyosarcoma cell line, A673. While 
growth inhibitory for a large number of tumor cell lines, TIF-1  stimulated the 
growth of several normal cell lines. Human TGF-~ was also shown (29) to either 
stimulate or inhibit cell growth, depending on the target cell and conditions of 
assay. Other growth factors, including EGF (30) and interleukin 2 (31, 32), were 
found to be growth inhibitory in some transformed cell lines. Hatakeyama et al. 
(32)  pointed out  that,  in  neoplastic cells,  growth factor-receptor interactions 
may lead to reverse signal transduction, i.e., produce growth inhibition instead 
of the growth stimulation seen in normal cells. It is tempting to speculate that 
TNF is primarily a growth factor, and that its direct cytostatic or cytotoxic effects 
on  transformed  cells  are  in  fact  the  result  of an  anomalous  growth  signal 
transduction in cells lacking the constraints of normal growth control mecha- 
nisms. 
All of the experiments reported in  this paper used the FS-4  line of human 
foreskin fibroblasts.  However, a similar growth-stimulatory effect was seen with 
TNF in the WI-38 line of diploid human embryo lung fibroblasts and two other 
lines of human skin fibroblasts (data not shown), indicating that TNF is a more 
general fibroblast growth factor. (Other types of nonneoplastic cells have not yet 
been examined.) It  is  possible  that  some of the earlier reports of monocyte/ 
macrophage-derived fibroblast growth factor activities (33-36) were due to the 
presence  of  TNF.  However,  TNF  is  apparently  not  the  only  mono- 
cyte/macrophage-derived protein exerting a growth-stimulatory effect on fibro- 
blasts, because a similar mitogenic effect was also shown (11) with IL-1. 
IFNs were shown to promote the cytotoxic activity of lymphotoxin or TNF in 
different transformed cells (17, 37-40). Synergism between IFNs and TNF may 
be partly due to the stimulation of TN F receptor expression by I FNs, particularly 
by IFN-3, (6). In contrast to the synergistic enhancement of TNF cytotoxicity by 
IFN-3,,  cell growth stimulatory activity of TNF  was inhibited in  FS-4 cells by 
IFN-3,  (Fig.  3) as well as IFN-/3 (data not shown). Earlier, IFNs were shown to 
inhibit cell growth in a variety of cell lines, and also to inhibit the stimulation of 
DNA synthesis by a variety of growth-promoting agents, including EGF, insulin, 
cholera toxin, and others (4 I). The mechanism responsible for the inhibition of 
cell growth by  IFNs has not yet been identified.  IFNs may act by inhibiting 640  FIBROBLAST  GROWTH STIMULATED BY TUMOR NECROSIS FACTOR 
growth factor-induced expression  of regulatory genes,  e.g.,  c-myc  (42).  Since 
IFNs and TNF or lymphotoxin are often produced by the same cell populations 
in  response  to  the  same  stimuli  (40),  both  the  synergistic and  antagonistic 
interactions  involving TNF  or  lymphotoxin and  IFNs  could  have  biological 
significance in vivo. 
Summary 
Tumor  necrosis  factor  (TNF)  is  a  monocyte-derived protein  cytotoxic or 
cytostatic for some tumor cell lines. Here we show that highly purified E.  coli- 
derived recombinant human TNF stimulated the growth of human FS-4 diploid 
fibroblasts. Stimulation of cell growth was demonstrable at a TNF concentration 
of 10 pg/ml (3 x  10  -~s M). Maximal stimulation was attained at TNF concentra- 
tions of 10 ng/ml (3 x  10  -~° M) or higher. Growth-stimulatory activity of TNF 
was inhibited by an  mAb neutralizing the cytotoxic activity of TNF.  Growth 
stimulation was not inhibited by another mAb specific for TNF, lacking neutral- 
izing activity for the cytotoxic activity of TNF. Growth stimulation by TNF was 
more marked and more sustained in the presence of_>l 0% FCS than in medium 
with _<5% FCS.  Addition of TNF to confluent FS-4  cultures also produced a 
marked stimulation of cell growth in the presence of fresh FCS, while a  much 
less marked stimulation was seen in the absence of FCS. Stimulation of confluent 
cultures by TNF in serum-free medium was enhanced by insulin, suggesting that 
insulin or insulin-like growth factor(s) in the serum can act synergistically with 
TNF in producing growth stimulation. While the growth-stimulatory effects of 
TNF and insulin were synergistic, the actions of TNF and epidermal growth 
factor (EGF) were less than additive, suggesting that TNF and EGF may activate 
identical or  similar pathways.  We  conclude that stimulation of cell  growth is 
probably a physiological function of TNF, and that the cytotoxic and cytostatic 
actions of TNF may be the result of an anomalous growth signal transduction in 
neoplastic cells lacking the constraints of normal growth control mechanisms. 
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